Morningside Healthcare is dedicated to providing quality products without compromise.
Our headline brands highlight our ability to bring bioequivalent products to the NHS, which has resulted in significant cost saving opportunities for CCG’s.
These benefits are in line with stated government policy to increase efficiencies in the NHS.
All our headline brands are widely available through mainline pharmaceutical wholesalers, and we ensure that sufficient stock levels are available to meet anticipated demands.
At Morningside Healthcare we are proud to provide our NHS partners with:
- Bioequivalent products with significant cost saving opportunities
- Reassurance of supply continuity
- Dedicated patient and healthcare professional websites for advice and support
- Free patient advice leaflets and template letters for prescribers
Summary of Product Characteristics (SmPC) for products listed below can be found here
In reference to Morningside Healthcare’s oral contraceptives (Levest®, Cimizt®, Lizinna® and Zelleta®), Dr Farook Al-Azzawi. Consultant Gynaecologist at Leicester Royal Infirmary said:
“
This is a wonderful – and rare – opportunity for CCGs to make impressive cost savings. It is not often that we have a chance to easily cut costs, and here we have it.
By simply changing the name of the drug and informing the patient that it is exactly the same contraceptive pill containing the same active ingredients, but with different name, packaging and manufacturer, we have the opportunity to save.
This process is so much easier than changing entire therapies, and then having consequent reviews and potential side effects to deal with. We can keep the treatment the same but a simple change to a branded generic can make vital financial savings across CCGs.
”
Dr Farook Al-Azzawi. Consultant Gynaecologist at Leicester Royal Infirmary
Please refer to full SmPC text before prescribing. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Morningside Healthcare Ltd.’s Medical Information Department on Tel: 0116 478 0322.
